₹3.08
▲ +0.01 +0.33%
18 Jul 2026
BSE Listed
GSM 0Transgene Biotek Ltd. (526139)
Volume: 2,080Avg Vol 1W: 41,502Avg Vol 1M: 35,14052W Range:₹1.83₹5.26
Key Ratios
Checked 10h agoMarket Cap₹23 Cr
Current Price₹3.08
Previous Close₹3.07
High / Low (52w)₹5.26 / ₹1.83
Volume2,080
Avg Vol (1W)41,502
Avg Vol (1M)35,140
Stock P/E—
Book Value₹1.11
Dividend Yield0%
ROE-19.73%
ROA-114.85%
Revenue (TTM)—
Revenue Growth—
Profit Margin-825%
Total Debt—
Shares Outstanding8 Cr
Face Value—
EPS (TTM)₹0
P/B2.79
Debt / Equity1.38
50 DMA₹3.08
200 DMA₹3.05
Day change+0.33%
SurveillanceGSM 0 (as of 2026-07-17)
Price Chart
₹3.08▼ 38.89% · 1Y
2025-07-172026-07-17
20-day avg volume: 36K shares
Pros
- Company is almost debt-free.
- Revenue grew 150% YoY.
Cons
- Company is loss-making at the latest annual result.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EBITDA | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹-1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹-1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| EBITDA | ₹-5 Cr | ₹-9 Cr | ₹-11 Cr | ₹-10 Cr | ₹-10 Cr | ₹-6 Cr | ₹-1 Cr | ₹0 Cr |
| Net Profit | ₹-6 Cr | ₹-9 Cr | ₹-11 Cr | ₹-10 Cr | ₹-10 Cr | ₹-6 Cr | ₹-1 Cr | ₹-1 Cr |
| EPS | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹187 Cr | ₹177 Cr | ₹167 Cr | ₹157 Cr | ₹147 Cr | ₹142 Cr | ₹142 Cr | ₹144 Cr |
| Total Liabilities | ₹134 Cr | ₹133 Cr | ₹134 Cr | ₹135 Cr | ₹130 Cr | ₹131 Cr | ₹132 Cr | ₹134 Cr |
| Equity | ₹52 Cr | ₹44 Cr | ₹33 Cr | ₹22 Cr | ₹17 Cr | ₹11 Cr | ₹11 Cr | ₹10 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹-1 Cr | ₹-2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Investing | ₹3 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹-2 Cr |
| Financing | ₹-2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Free Cash Flow | ₹-1 Cr | ₹-2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Shareholding
Promoter 23.64% Institutions 0% Public 76.36%
Efficiency & Working Capital
ROCE-2.3%
Interest Coverage-1.8
Dividend Payout—
Debtor Days12 d
Inventory Days48 d
Payable Days2231 d
Cash Conversion Cycle-2172 d
Working Capital Days59 d
Shareholding Details
As of 2026-06-30
Promoter23.6%
FII0%
DII0%
Institutions0%
Public76.4%
Promoter Pledge0%
No. of Shareholders13,817
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% | 23.6% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% | 76.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 11,360 | 12,220 | 12,426 | 12,766 | 12,963 | 13,307 | 13,583 | 13,475 | 13,461 | 13,545 | 13,767 | 13,817 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Dr K Koteswara Rao | Shareholding of Promoter and Promoter Group | 21.9% | 1.52 Cr |
| Kollipara Nirmala | Shareholding of Promoter and Promoter Group | 1.7% | 11,92,000 |
| Kollipara Srinivas | Shareholding of Promoter and Promoter Group | 0% | 24,000 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Dr K Koteswara Rao | 0 | 0% | 2026-06-30 |
| Kollipara Nirmala | 0 | 0% | 2026-06-30 |
| Kollipara Srinivas | 0 | 0% | 2026-06-30 |
| Dr K Koteswara Rao | 0 | 0% | 2026-03-31 |
| Kollipara Nirmala | 0 | 0% | 2026-03-31 |
| Kollipara Srinivas | 0 | 0% | 2026-03-31 |
| Dr K Koteswara Rao | 0 | 0% | 2025-12-31 |
| Kollipara Nirmala | 0 | 0% | 2025-12-31 |
| Kollipara Srinivas | 0 | 0% | 2025-12-31 |
| Dr K Koteswara Rao | 0 | 0% | 2025-09-30 |
| Kollipara Nirmala | 0 | 0% | 2025-09-30 |
| Kollipara Srinivas | 0 | 0% | 2025-09-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| K Koteswara Rao | Chairman & Managing Director | 2025 |
| Sujana Kadiam | Independent Non Exe. Director | 2025 |
| Swetha Marri | Independent Non Exe. Director | 2025 |
| Santosh Kumar | Independent Non Exe. Director | 2025 |
| Ankita Jain | Company Secretary | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Diagnostic Services | ₹0 Cr | 24.6% |
| CRO Services | ₹0 Cr | 75.4% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 76 | 76 | 76 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 1 | 0 | 1 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 1 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
Company Information
🌐 www.transgenebiotek.com ↗
📍 Plot No 69 & 70 IDA Bollaram, Sangareddy, Telangana, 502325
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search